Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Marsh & McLennan Companies, Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Marsh & McLennan Companies, Inc. trades at $179.94 (market cap $84.47B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 9.5× Kymera Therapeutics Inc. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| KYMR | MRSH | |
|---|---|---|
Market Cap | $8.87B | $84.47B |
Volume | 779,107 | 3,662,234 |
Sector | Health | Financials |
52-Week High | $127.31 | $203.85 |
52-Week Low | $55.80 | $157.32 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $8.26B | $105.15B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marsh (MRSH) trades at $178.40, up 1.05% today, with a bullish technical signal and recent earnings beats. The stock shows strong fundamentals with a P/E of 21.61, net income margin of 14.24%, and consistent revenue growth to $27.0B in 2025. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) enhances its advisory services, while analyst consensus is a 'Hold' with a $202.71 price target. Cash flow remains positive at $486M in 2025, supporting dividend payments.
Outlook is cautiously optimistic; the stock offers growth potential from strategic acquisitions and solid profitability, but risks include high P/B of 5.56 and competitive pressures. Investors should weigh the 13.6% upside to the consensus target against overbought RSI levels and margin compression risks in 2026 forecasts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
